ADMA Biologics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
ADMA develops plasma-based biologics for immune-compromised patients and operates an FDA-licensed, GHA-certified source-plasma collection center in Georgia. Its lead candidate, RI-002, is being developed for primary immunodeficiency disease. This unaudited report covers the three months ended March 31, 2014, compared with the three months ended March 31, 2013.
Financial Results and Key Metrics
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Total revenue | $1.561 million | $0.793 million | +97% |
| Gross profit | $0.584 million | $0.264 million | More than doubled |
| Gross margin | Approximately 37.4% | Approximately 33.3% | Improved |
| Operating loss | $(5.684) million | $(3.150) million | Loss increased |
| Net loss | $(5.904) million | $(3.242) million | Loss increased 82% |
| Basic and diluted loss per share | $(0.64) | $(0.55) | Higher loss per share |
| Cash flow from operations | $(5.040) million | $(3.075) million | Greater cash use |
- Product revenue was $1.542 million, primarily from plasma sales to Biotest; license revenue was $18,889. The company had not generated revenue from its therapeutics research and development business.
- Research and development expense increased to $4.330 million from $1.468 million, mainly due to manufacturing and production activities for the RI-002 Phase III program.
- Plasma center operating expense increased 56% to $802,469 as donor collections expanded. General and administrative expense decreased 21% to $1.135 million, primarily because of lower financing-related professional fees.
- Cash and cash equivalents were $26.518 million at March 31, 2014, compared with $26.149 million at December 31, 2013. Short-term investments were $2.203 million.
- Total current assets were $30.788 million and total current liabilities were $4.303 million. The filing describes working capital as approximately $26.5 million.
- Notes payable, net of debt discount, were $9.674 million, compared with $4.865 million at year-end 2013. Total liabilities increased to $16.048 million from $10.407 million.
- Net cash provided by investing activities was $620,195, including $732,143 of proceeds from short-term investments, partly offset by $111,948 of equipment purchases.
- Net cash provided by financing activities was $4.789 million, primarily from $4.850 million of net Hercules loan proceeds.
Material Changes Versus the Prior Comparable Period
- Revenue nearly doubled because of increased plasma donor collections, advertising and promotions, and expanded donor equipment.
- Gross profit increased to $583,529 from $263,889, while gross margin improved to approximately 37.4% from 33.3%.
- Operating expenses increased 84% to $7.245 million. The principal driver was the more than doubling of R&D expense as clinical drug manufacturing for RI-002 was completed during the quarter.
- Net loss increased by $2.662 million, and operating cash consumption increased by $1.966 million.
- Interest expense increased to $226,885 from $128,796 due to higher debt and the amortization of debt discounts and deferred financing costs.
- Weighted-average shares outstanding increased to 9.292 million from 5.871 million, following the company’s October 2013 initial public offering.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- ADMA had completed enrollment of 59 patients at nine treatment centers in its pivotal Phase III RI-002 trial. Management expected preliminary data in the fourth quarter of 2014, a potential BLA filing in the first half of 2015, and potential first commercial sales as early as the first half of 2016, subject to successful results and FDA approval.
- Management expected R&D expense and G&A expense to increase during the remainder of 2014 as RI-002 development and staffing continued.
- Management believed available cash, short-term investments, projected revenue and potential credit-facility funds would finance operations into the first half of 2016. This outlook depends on assumptions regarding expenses, revenue, clinical development and financing availability; additional capital may be required sooner.
- The amended Hercules facility permits borrowing of up to $15.0 million. The company borrowed $10.0 million at the February 24, 2014 closing, including refinancing of existing Hercules debt, and may access an additional $5.0 million if specified Phase III endpoints support a BLA filing. The loan is secured by company assets, excluding intellectual property, and includes financial and operational covenants and events of default.
- Hercules warrants were recorded as a liability at a March 31, 2014 fair value of $214,368 and are subject to periodic fair-value adjustments. The quarter included a $5,220 favorable change in warrant fair value.
- The company has incurred cumulative losses of approximately $58.5 million and has experienced negative operating cash flow since inception. Failure to obtain additional financing could require reductions or delays in research, clinical trials or commercialization and could ultimately threaten continued operations.
- Revenue is substantially concentrated in one customer. The company also depends on regulatory approval, successful clinical results, manufacturing capabilities, donor collections, key personnel and potential partners. The filing states that no current legal proceedings are expected to have a material adverse effect.
- Minimum rent obligations under Georgia facility leases totaled approximately $3.4 million through the end of the lease terms.
Important Facts for Investors to Verify
- Progress, safety and efficacy results from the RI-002 Phase III trial and the timing and contents of any BLA filing.
- Whether plasma revenue concentration in Biotest continues and whether collection growth produces sustainable positive margins.
- Actual cash burn versus the forecast supporting funding into the first half of 2016.
- Availability and conditions of the additional $5.0 million Hercules tranche, debt repayment beginning in 2015, and compliance with loan covenants.
- Future financing requirements, potential dilution, warrant-related fair-value volatility and the ability to obtain capital on acceptable terms.
- FDA approval risk, manufacturing readiness and the timing of potential RI-002 commercialization; the filing does not establish that approval or commercial sales will occur.